A new meta-analysis in the May 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network provides updated evidence that methylphenidate-type psychostimulants-a class of medication that increases dopamine and norepinephrine availability in the brain-can provide meaningful relief for cancer-related fatigue.
To continue reading click here
